Auspherix Ltd, an early-stage anti-infectives company, has appointed Jared Silverman to its board of directors and scientific advisory board to help guide the development of a new class of antibacterials. Dr Silverman is currently vice president of research at the US microbiome company VL32 Inc. Previously he worked at Cubist Pharmaceuticals Inc which is now part of Merck & Co Inc.
Also appointed as a scientific advisor is David Livermore, a professor of medical microbiology at the University of East Anglia and a member of the UK government’s advisory committee on antimicrobial resistance and healthcare associated infections.
Auspherix is working on compounds that could potentially treat both Gram-negative and Gram-positive infections.
Auspherix announced the appointments on 22 July 2015.
Copyright 2015 Evernow Publishing Ltd